454 results on '"Laskin, J."'
Search Results
2. Molecular composition of particulate matter emissions from dung and brushwood burning household cookstoves in Haryana, India
3. Effect of relative humidity on the composition of secondary organic aerosol from the oxidation of toluene
4. Molecular Diversity of Sea Spray Aerosol Particles: Impact of Ocean Biology on Particle Composition and Hygroscopicity
5. NRG1 fusion-driven tumors: biology, detection, and the therapeutic role of afatinib and other ErbB-targeting agents
6. Osimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis
7. Complex refractive indices in the near-ultraviolet spectral region of biogenic secondary organic aerosol aged with ammonia
8. Effect of humidity on the composition of isoprene photooxidation secondary organic aerosol
9. Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial
10. Association between walking 5000 step/day and fall incidence over six months in urban community-dwelling older people
11. Immune Activation following Irbesartan Treatment in a Colorectal Cancer Patient: A Case Study
12. Response to angiotensin blockade with irbesartan in a patient with metastatic colorectal cancer
13. LBA4 Preliminary safety and efficacy of adagrasib with pembrolizumab in treatment-naïve patients with advanced non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation
14. 1110P Clinical outcomes for EGFR/HER2 exon 20 insertion-mutated NSCLC
15. 964P PACIFIC on the West Coast: Exploring reasons for not receiving consolidative durvalumab in the treatment of locally advanced lung cancer
16. EP04.02-004 The Patient Impact of Liquid Biopsy - Health-Related Quality of Life in Patients Undergoing Liquid Biopsy for Advanced Non-Small Cell Lung Cancer
17. EP08.02-108 Osimertinib Long-Term Tolerability in Patients with EGFRm NSCLC Enrolled in the AURA Program or FLAURA Study
18. 960P Beyond PACIFIC: Real-world outcomes of adjuvant durvalumab according to treatment received and PD-L1 expression
19. Successful targeting of the NRG1 pathway indicates novel treatment strategy for metastatic cancer
20. OA16.02 The Economic Value of Liquid Biopsy for Genomic Profiling in Advanced Non-Small Cell Lung Cancer
21. P28.02 Beyond PACIFIC: Outcomes and Toxicity According to Durvalumab Dosing Schedule Every 2 versus 4 Weeks
22. A randomized, phase II trial of cetuximab with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer
23. Segregation at a Locus Determining an Immunoglobulin Genetic Marker for the Light Chain Variable Region Affects Inheritance of Expression of an Idiotype
24. 2129P Feasibility of a virtual exercise program to mitigate decline in physical function for advanced lung cancer patients
25. LBA65 KRYSTAL-7: Efficacy and safety of adagrasib with pembrolizumab in patients with treatment-naïve, advanced non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation
26. 1406P Outcomes of patients with metastatic EGFR mutant lung cancer requiring dose modifications of first line osimertinib
27. P89.03 Demonstrating VALUE of Liquid Biopsy for Lung Cancer in a Public Healthcare System
28. P21.05 Overall Survival by PD-L1 Status in Stage III NSCLC Following Implementation of Durvalumab: The Real-World Application of PACIFIC
29. 1247P Uptake of durvalumab in the management of stage III NSCLC: The real-world application of PACIFIC
30. 1195P The value of detecting resistance through liquid biopsy
31. Overall survival (OS) from the AURA3 phase III study: Osimertinib vs platinum-pemetrexed (plt-pem) in patients (pts) with EGFR T790M advanced non-small cell lung cancer (NSCLC) and progression on a prior EGFR-tyrosine kinase inhibitor (TKI)
32. Ryanodine-Sensitive Calcium Flux Regulates Motility of Arbacia punctulata Sperm
33. P1.01-40 EGFR ctDNA Detection: The Impact of Site of Progression and Burden of Progressive Disease
34. NRG1-fusion positive gastrointestinal tumours: afatinib as a novel potential treatment option
35. Canadian Consensus: Oligoprogressive, Pseudoprogressive, and Oligometastatic Non-Small-Cell Lung Cancer
36. FUS-NFATc2 sarcoma of bone, a novel molecular entity with aggressive behavior: Clinical and molecular pathology findings of two cases
37. ASTRIS real world study of osimertinib in patients (pts) with EGFR T790M NSCLC: Efficacy analysis by tissue or plasma T790M test
38. Personalized oncogenomics in the management of gastrointestinal carcinomas&mdash
39. Patient reported stressors in the practical domain of a cancer diagnosis: The impact of socioeconomic status and geographic location
40. MA14.07 The Impact of Socioeconomic Status and Geographic Location on Palliative Chemotherapy Uptake in Patients with Metastatic NSCLC
41. MA02.11 Achieving Value in Cancer Diagnostics: Blood Versus Tissue Molecular Profiling - A Prospective Canadian Study (VALUE)
42. P2.13-13 Real-World Study of Osimertinib in EGFR T790M-Mutated Non-Small Cell Lung Cancer (NSCLC): ASTRIS Canadian Cohort Analysis
43. Clinical benefit of whole genome and transcriptome analysis (WGTA) in metastatic colorectal cancer (MCRC): Results from the personalized oncogenomics program (POG)
44. MA14.05 Social Isolation Increases Psychological Distress in Patients With NSCLC
45. OA 10.01 Detection of EGFR mutations from plasma ctDNA in the osimertinib Phase III trial (AURA3): comparison of three plasma assays
46. P1.03-020 Detection of Hypoxia Using EF5 PET/CT in 10 Patients with Advanced NSCLC Receiving Chemotherapy with and without Bevacizumab
47. P3.01-019 Canadian Multicenter Validation Study of Plasma Circulating Tumor DNA for Epidermal Growth Factor (EGFR) T790M Testing
48. P3.01-062 The Perceived Value of Avoiding Biopsy: Patients' Willingness to Pay for Circulating Tumor DNA T790M Testing
49. MA 04.02 Assessing the Psychosocial Needs of Newly Diagnosed NSCLC Patients: Identifying the Population Most At-Risk
50. Kinetic energy release for metastable fullerene ions
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.